|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1571-1579.
Prepublished online as a Blood First Edition Paper on April 27, 2006; DOI 10.1182/blood-2006-02-004747.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn,
Erik A. Nelson,
Mehrdad Mohseni,
Fabrice Porcheray,
Haesook Kim,
Despina Litsa,
Roberto Bellucci,
Elke Raderschall,
Christine Canning,
Robert J. Soiffer,
David A. Frank, and
Jerome Ritz
From the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
IL-2 plays a critical role in the maintenance of CD4+CD25+ FOXP3+ regulatory T cells (Tregs) in vivo. We examined the effects of IL-2 signaling in human Tregs. In vitro, IL-2 selectively up-regulated the expression of FOXP3 in purified CD4+CD25+ T cells but not in CD4+CD25- cells. This regulation involved the binding of STAT3 and STAT5 proteins to a highly conserved STAT-binding site located in the first intron of the FOXP3 gene. We also examined the effects of low-dose IL-2 treatment in 12 patients with metastatic cancer and 9 patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. Overall, IL-2 treatment resulted in a 1.9 median fold increase in the frequency of CD4+CD25+ cells in peripheral blood as well as a 9.7 median fold increase in FOXP3 expression in CD3+ T cells. CD56+CD3- natural killer (NK) cells also expanded during IL-2 therapy but did not express FOXP3. In vitro treatment of NK cells with 5-aza-2'-deoxycytidine restored the IL-2 signaling pathway leading to FOXP3 expression, suggesting that this gene was constitutively repressed by DNA methylation in these cells. Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Nagar, H. Vernitsky, Y. Cohen, D. Dominissini, Y. Berkun, G. Rechavi, N. Amariglio, and I. Goldstein
Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells
Int. Immunol.,
July 9, 2008;
(2008)
dxn062v2.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Bayer, J. Y. Lee, A. de la Barrera, C. D. Surh, and T. R. Malek
A Function for IL-7R for CD4+CD25+Foxp3+ T Regulatory Cells
J. Immunol.,
July 1, 2008;
181(1):
225 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bonelli, A. Savitskaya, K. von Dalwigk, C. W. Steiner, D. Aletaha, J. S. Smolen, and C. Scheinecker
Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE)
Int. Immunol.,
July 1, 2008;
20(7):
861 - 868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hennighausen and G. W. Robinson
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B
Genes & Dev.,
March 15, 2008;
22(6):
711 - 721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Passerini, S. E. Allan, M. Battaglia, S. Di Nunzio, A. N. Alstad, M. K. Levings, M. G. Roncarolo, and R. Bacchetta
STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells
Int. Immunol.,
March 1, 2008;
20(3):
421 - 431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-R. Pallandre, E. Brillard, G. Crehange, A. Radlovic, J.-P. Remy-Martin, P. Saas, P.-S. Rohrlich, X. Pivot, X. Ling, P. Tiberghien, et al.
Role of STAT3 in CD4+CD25+FOXP3+ Regulatory Lymphocyte Generation: Implications in Graft-versus-Host Disease and Antitumor Immunity
J. Immunol.,
December 1, 2007;
179(11):
7593 - 7604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Kang, H. W. Lim, O. M. Andrisani, H. E. Broxmeyer, and C. H. Kim
Vitamin A Metabolites Induce Gut-Homing FoxP3+ Regulatory T Cells
J. Immunol.,
September 15, 2007;
179(6):
3724 - 3733.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Juszczynski, J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
PNAS,
August 7, 2007;
104(32):
13134 - 13139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Clayton, J. P. Mitchell, J. Court, M. D. Mason, and Z. Tabi
Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2
Cancer Res.,
August 1, 2007;
67(15):
7458 - 7466.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-P. Kim and W. J. Leonard
CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation
J. Exp. Med.,
July 9, 2007;
204(7):
1543 - 1551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Chen, M. Baumel, D. N. Mannel, O. M. Z. Howard, and J. J. Oppenheim
Interaction of TNF with TNF Receptor Type 2 Promotes Expansion and Function of Mouse CD4+CD25+ T Regulatory Cells
J. Immunol.,
July 1, 2007;
179(1):
154 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Sanchez-Guajardo, C. Tanchot, J. T. O'Malley, M. H. Kaplan, S. Garcia, and A. A. Freitas
Agonist-Driven Development of CD4+CD25+Foxp3+ Regulatory T Cells Requires a Second Signal Mediated by Stat6
J. Immunol.,
June 15, 2007;
178(12):
7550 - 7556.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bostik, E. S. Noble, S. T. Stephenson, F. Villinger, and A. A. Ansari
CD4+ T Cells from Simian Immunodeficiency Virus Disease-Resistant Sooty Mangabeys Produce More IL-2 Than Cells from Disease-Susceptible Species: Involvement of p300 and CREB at the Proximal IL-2 Promoter in IL-2 Up-Regulation
J. Immunol.,
June 15, 2007;
178(12):
7720 - 7729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yao, Y. Kanno, M. Kerenyi, G. Stephens, L. Durant, W. T. Watford, A. Laurence, G. W. Robinson, E. M. Shevach, R. Moriggl, et al.
Nonredundant roles for Stat5a/b in directly regulating Foxp3
Blood,
May 15, 2007;
109(10):
4368 - 4375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J.J. van derVliet, H. B. Koon, S. C. Yue, B. Uzunparmak, V. Seery, M. A. Gavin, A. Y. Rudensky, M. B. Atkins, S. P. Balk, and M. A. Exley
Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer
Clin. Cancer Res.,
April 1, 2007;
13(7):
2100 - 2108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Zheng, J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz
IL-2 Is Essential for TGF-beta to Convert Naive CD4+CD25- Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells
J. Immunol.,
February 15, 2007;
178(4):
2018 - 2027.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Burchill, J. Yang, C. Vogtenhuber, B. R. Blazar, and M. A. Farrar
IL-2 Receptor beta-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells
J. Immunol.,
January 1, 2007;
178(1):
280 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Battaglia, A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M.-G. Roncarolo
Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients
J. Immunol.,
December 15, 2006;
177(12):
8338 - 8347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Zorn and J. Ritz
Studying Human Regulatory T Cells In vivo.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5265 - 5267.
[Full Text]
[PDF]
|
 |
|
|
|